StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $2.50 price objective on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Trading Up 3.8 %

VolitionRx stock opened at $0.74 on Tuesday. The stock has a market cap of $61.74 million, a P/E ratio of -1.62 and a beta of 1.14. The company has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.82. VolitionRx has a 12-month low of $0.55 and a 12-month high of $1.40.

VolitionRx (NYSE:VNRX) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. As a group, sell-side analysts forecast that VolitionRx will post -0.31 earnings per share for the current fiscal year.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.